Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in chronic kidney disease (cardio-renal outcomes)
jRCT2080224111Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and cardiac morbidity comparing Empagliflozin 10 mg with Placebo (2 arms). Started Oct 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)cardiac morbidity
Beyond the preview
Go deeper on jRCT2080224111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224111.